12-Week, Open-Label, Multi-Center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients.
Phase of Trial: Phase IV
Latest Information Update: 30 Aug 2011
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ADAPT
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.